Johnson & Johnson talc settlement supports shares as healthcare rotation adds momentum

Traders Union
All News
Financial News
J&J talc settlement boosts shares

Highlights

Johnson & Johnson agreed to a $5.5 billion talc settlement, lower than the earlier $8 billion proposal, pending support from at least 95% of claimants.
Darzalex posted second-quarter sales over $4.2 billion, up nearly 19%, while Carvykti and Tecvayli grew nearly 50% and 57%, supporting oncology leadership goals.
Healthcare sector rotation in July boosts Johnson & Johnson shares as investors seek defensive stocks over declining information technology names.

Settlement terms and litigation backdrop

As reported by CNBC, the latest gain in Johnson & Johnson shares follows the company’s Monday evening announcement that it has reached a deal covering about 76,000 ovarian cancer cases linked to talc-based baby powder and other talc products. The proposed settlement totals $5.5 billion, with $3 billion scheduled for payment in 2027 and no further payments before 2028, and it depends on support from at least 95% of claimants.

The agreement marks a lower figure than the $8 billion proposal Johnson & Johnson put forward two years earlier through a bankruptcy process that a judge rejected. Leerink analysts say the revised amount is a positive development because it comes in below the 2024 proposal, while the company continues to argue that the ovarian cancer and mesothelioma claims are meritless and unsupported by science or reliable expertise.

Johnson & Johnson says studies show talc is safe, does not contain asbestos and does not cause cancer. Even so, the company stopped selling talc-based baby powder in North America in 2020 and worldwide by 2023, as it worked through years of litigation over the products.

Drug pipeline and defensive sector shift support outlook

Beyond the legal resolution, investor interest in Johnson & Johnson is also tied to its performance in pharmaceuticals and medical technology. The company’s multiple myeloma treatment Darzalex posts second-quarter sales of more than $4.2 billion, up nearly 19% from a year earlier, while Carvykti and Tecvayli continue strong growth of nearly 50% and 57%, respectively.

Chief Executive Joaquin Duato says Johnson & Johnson is on track to become the number one oncology company by 2030, with projected sales above $50 billion. Outside oncology, the company is advancing newer assets including Icotyde, which won FDA approval in March as the first oral IL-23 inhibitor for moderate-to-severe plaque psoriasis, and Ottava, its robotic surgical system, which later won U.S. approval for several general surgery procedures.

The stock is also benefiting from a broader market rotation into defensive sectors. Healthcare stocks outperform in July while information technology shares decline, reinforcing what Jim Cramer describes as a "J&J market" as investors move away from more volatile artificial intelligence trades.

Our earlier coverage examined the broad rotation in U.S. equities toward quality stocks as leadership cools in parts of the technology sector. It highlighted how investors are favoring companies with strong free cash flow, solid balance sheets and durable margins, with health care among the groups benefiting from the shift alongside dividend-oriented names.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.